IMUGENE LIMITED — Board/Management Information 2015

Aug 26, 2015

==> picture [167 x 53] intentionally omitted <==

Genentech Leader in Oncology Appointed Imugene Chief Operating Officer

• Immuno-oncology specialist Leslie Chong appointment effective immediately and moving from San Francisco to Sydney

• Genentech is the global leader in immuno-oncology and developer of Herceptin. Genentech employs nearly 13,000 people and was fully acquired by Roche in 2009 with a final payment of USD46.8B

Melbourne, Australia, 27 August 2015: Imugene Limited (ASX: IMU), a clinical stage immunooncology company, has appointed former Genentech leader in oncology Ms Leslie Chong as Imugene COO, effective mid September.

Most recently, Ms Chong was a Senior Clinical Program Leader at Genentech, Inc., in San Francisco. Genentech is widely regarded as one of the world’s most successful biotech companies with a strong oncology franchise including the best-selling breast cancer drug Herceptin.

Currently based in San Francisco, Ms Chong will relocate to Sydney within the month.

Executive Chairman Mr Paul Hopper said, “We are delighted that someone of Leslie’s calibre, deep immuno-oncology experience, industry networks, and from one of the world’s most successful and prestigious drug developers, has agreed to join our team. IMU is at an important stage of its clinical development and Leslie’s deep, hands-on clinical trial experience across many studies will be invaluable to us.”

Ms Chong said, “Immuno-oncology is revolutionising the treatment of cancer and I believe Imugene’s technology shows great promise. The compelling science against the validated Her-2 target, a world-class drug development team in Dr Axel Hoos and Professor Ursula Weidermann, and the opportunity to build out additional pipeline with Imugene’s mimotope technology, provides a very sound foundation for future success. I look forward with great enthusiasm to working with the Imugene team.”

Also, Managing Director Mr Charles Walker will step down as Managing Director and continue his involvement as a non-executive director of Imugene.

Paul Hopper said, “Charlie has provided outstanding leadership over the past 12 months and has been instrumental in laying the groundwork for our Phase 1b/2 trial in addition to securing the manufacture of our vaccine material for that trial. We look forward to his continued contribution as a Board member.”

About Imugene:

Imugene (ASX; IMU) is a clinical stage immuno-oncology company developing HER-2+ gastric and breast cancer immunotherapies. The Company’s lead product is HER-Vaxx, a proprietary HER-2 positive cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor overexpressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase 1 study in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer.

For more information, please contact:

Media contact: Imugene: Rudi Michelson Paul Hopper Monsoon Communications Executive Chairman +61 (0)3 9620 3333 +61 (0) 406 671 515 rudim[at]monsoon.com.au receptogen[at]earthlink.net

IMUGENE LIMITED Telephone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com